Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Center, Korea
NRG Oncology
Mayo Clinic
Janssen Research & Development, LLC
Aarhus University Hospital
Janssen Research & Development, LLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
UroGen Pharma Ltd.
UroGen Pharma Ltd.
National Cancer Institute (NCI)
Aarhus University Hospital
First Affiliated Hospital of Wenzhou Medical University
Abnoba Gmbh